Nucleic acid fragment binding to target protein
An object of the present invention is to develop and provide a method for efficiently producing a nucleic acid aptamer, particularly, a DNA aptamer, having higher specificity and binding activity against a target substance than those of nucleic acid aptamers obtained by conventional methods. The present invention provides a transcribable or replicable nucleic acid aptamer comprising a natural nucleotide and a non-natural nucleotide having an artificial base-pairable artificial base. The present invention also provides a method for sequencing a non-natural nucleotide-containing single-stranded nucleic acid molecule selected from a single-stranded nucleic acid library.
1. A transcribable or replicable nucleic acid aptamer comprising:
natural nucleotides and
non-natural nucleotides having an artificial base-pairable artificial base,
wherein the artificial base is selected from the group consisting of 7-(2-thienyl)-3H-imidazo [4 5-b] pyridin-3-yl 2-nitropyrrol-1-yl, and 2-formyl-1H-pyrrol-1-yl, and
wherein the nucleic acid aptamer is directed against a vascular endothelial growth factor as a target substance,
wherein the nucleic acid aptamer comprises any one nucleotide sequence selected from the group consisting of SEQ ID NOs: 25 to 73, 80 to 104, 106 to 109, 111, and 115 to 166 (provided that “n” in the sequences represents 7-(2-thienyl)-3H-imidazo[4,5-b]pyridin-3-y]), 175, 177, 179, 181, 183, 198, 201, 202, 205 to 209, 211, 212, and 229 to 278.
2. The nucleic acid aptamer according to claim 1 ,
wherein the artificial base includes an artificial base-pairable derivative of the artificial base.
3. The nucleic acid aptamer according to claim 1 ,
wherein the content of the non-natural nucleotide is 20% or less of the total number of nucleotides.
4. The nucleic acid aptamer according to claim 1 ,
wherein the nucleic acid is a DNA or an RNA.
5. The nucleic acid aptamer according to claim 1 ,
wherein the nucleic acid aptamer consists of any one nucleotide sequence according to claim 1 that is 5′ flanked by the nucleotide sequence represented by SEQ ID NO: 1 and 3′ flanked by the nucleotide sequence represented by SEQ ID NO: 2.
6. A pharmaceutical composition which comprises a nucleic acid aptamer according to claim 1 as an active ingredient and functionally inhibits a target substance of the nucleic acid aptamer.
7. A pharmaceutical composition for functional inhibition of a vascular endothelial growth factor, comprising a nucleic acid aptamer according to claim 1 as an active ingredient.